IMARC Study Forecasts the Chinese diabetes market to exceed US$ 2.8 Billion by 2015

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. Further fuelled by rising disposable incomes, the diabetes market- Non-Insulin Anti-diabetics and Insulin, is expanding by more than 25% percent a year, and thus creating lucrative opportunities for global pharmaceutical companies at a time when rates in the more developed markets have declined.

China’s diabetes market grew at CAGR of 26% in the last five years with sales touching US$ 642 Million in 2009. In a country with around 10% of the total population being above 65 years of age, nearly 100 Million people obese and overweight, and with urbanization rates in an increasing mode, we expect the market to more than quadruple vis-à-vis its present level by 2015.

IMARC’s new report “China Diabetes Market Report & Outlook for 2010-2015” gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other.

Report Highlights

· Driven by strong performance of both Insulin and Non-Insulin Anti-diabetics, The Chinese diabetes market is expected to exceed US$ 2.8 Billion by 2015.

· In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four of the top five players were foreign multinationals, with Bayer being the leader with a 28% market share.

· Alpha Glycosidase Inhibitors represented the biggest non Insulin Anti-diabetes class with a share of 35% in 2009.

· Although DPP-IV Inhibitors have been available in China only since march 2010. We expect this class to show a strong uptake in the next five years and reach revenues worth US$ 172 Million.

· China’s Insulin market witnessed a CAGR growth of 31% between 2005-2009 and was worth US$ 285 Million in 2009.

· The Chinese Insulin market is strongly oligopolistic with top three players (all of them being multinationals) accounting for 92% of the total sales in 2009. In fact, one player (Novo Nordisk) accounted 71% of the total sales.

Forecasts: The report provides forecasts on:

· Number of diabetes patients

· Diagnosis and treatment rates in China

· Diabetes market

· Non-Insulin Anti-diabetics market

. Alpha-Glycosidase Inhibitors

. Glinides

. Glitazones

. Sulphonylureas

. DPP-IV Inhibhitors

. Biguanides

. GLP-1 Agonists

. All other Non-Insulin Anti-diabetic classes

· Insulin market


Competitive Landscape: This section covers:

· 2005-2009 sales and market shares of top players in the diabetes market

· 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market

· 2005-2009 sales and market shares of top players in various Non-Insulin Drug Classes

· 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin Drug Classes

· 2005-2009 sales and market shares of top players in the Insulin market

· 2005-2009 sales of top drugs comprising the portfolio of Key players in the Insulin market.


Key Questions Answered in this report

· What is the total size of the diabetes population in China and what are its characteristics?

· What are the diagnosis and drug treatment rates for diabetes in China?

· What are the key factors driving the growth of diabetes medication in China?

· What is the Size and Breakup of the total diabetes market in China?

· What is the Size and Breakup of the total Non-Insulin Anti-diabetics market in China?

· What is the Size and Breakup of the total Insulin market in China?

· Who are the key players in the Chinese diabetes market and how have they performed?

· What is the outlook of the Chinese diabetes market in the next five years?

· Which new products are expected to be launched in the next five years?

· Which therapy classes will show the highest growth in the next five years?

· What are the road blocks in the Chinese diabetes market?

To get the full version of "China diabetes market report and outlook for 2010-2015" please get in touch with us by emailing us at sales@imarcgroup.com or you can call us on +91-11-43095788

About IMARC

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

IMARC Group
Eastend Apartment Mayur Vihar Phase-1 Extention Delhi-110096, India
press@imarcgroup.com
+91-11-43095788

This release was published on openPR.